Articles tagged with Carcinoma
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Researchers developed AI-based methods to analyze microscopic tissue images and molecular information, revealing genetic and protein profiles of tumor clones. The approach enabled the identification of distinct cell populations within a tumor, which differ in gene activity and protein function.
The study identified RTN4IP1 as a factor associated with poor prognosis in triple-negative breast cancer, promoting metastasis through NAD⁺ depletion and disrupting glycolysis and oxidative phosphorylation. RTN4IP1 interacts with AK4 to cause this metabolic disruption.
A new wearable electric-field device has been shown to slow the growth and spread of aggressive breast cancer in preclinical models. The technology uses low-intensity electric fields that interact with cancer cells in a controlled way, reducing tumor growth and increasing immune responses.
A collaborative study between Insilico Medicine and top research institutions uses AI to identify therapeutic targets for IP-SNSCC, a rare and aggressive subset of head and neck cancers. The study provides the first comprehensive molecular atlas of this disease, enabling future translational research.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
Researchers found that glandular and squamous cancer cells share a common origin but diverge early in tumor development. This discovery challenges the long-standing debate over whether each cancer subtype originates from distinct cells or a single multipotent cell.
A comprehensive review of breast cancer risk models in women with a family history found that none are highly accurate at identifying which women will develop the disease. The BOADICEA model showed balanced performance, while others had significant limitations, emphasizing the need for continued improvement.
Research identifies HMGB3 as a critical driver of malignancy in ESCC, enhancing cell proliferation, migration, and invasion. TGIF2-mediated HMGB3 overexpression drives the oncogenic cascade through the TLR3/TGF-β axis, promoting tumor progression and metastasis.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A new study has identified the WWOX protein as a molecular guardian that prevents common skin tumors from undergoing a dangerous metamorphosis and spreading to other parts of the body. The loss of this protein allows cancer cells to transform into more aggressive, invasive forms.
Researchers from Institute of Science Tokyo reveal the SPP1–CD44–Hedgehog signaling pathway as a key driver of fibrosis in liver tumors, hinting at its potential as a therapeutic target. The study provides valuable insights into how liver tumors actively shape their surroundings, driving the onset and progression of fibrosis.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
A study by RIKEN researchers identifies a MYCN-driven biomarker that predicts the risk of liver cancer. The biomarker, known as the MYCN niche score, uses machine learning to analyze gene expression patterns and indicates whether a tumor-free liver is at high risk for developing tumors.
Scientists have identified the FOXO1-KLHL6 axis as a novel therapeutic target to enhance T cell-mediated immune response against tumors. The research found that persistent T cell receptor signaling suppresses the transcription factor FOXO1, leading to the downregulation of the E3 ubiquitin ligase KLHL6 and promoting T cell exhaustion.
Smoking exposure induces tumor microenvironment promoting sorafenib resistance in HCC by modifying the 14-3-3η proteome. Arsenic trioxide suppresses tumor progression with synergistic effect when combined with sorafenib.
Adrenocortical carcinoma is a rare but aggressive malignancy that requires personalized mitotane treatment to maximize efficacy and minimize toxicity. Optimal plasma concentrations between 14–20 mg/L are crucial for effective disease management.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.
A study led by Brazilian researchers has reconstructed the brain environment in the lab, revealing live interactions between cancer and healthy tissue. The 3D model allows real-time observation of brain metastases and has potential to reshape future therapies against metastatic melanoma.
Researchers identified miR-21 as a key regulator of bladder cancer growth and spread, highlighting its potential as a therapeutic target and diagnostic biomarker. By inhibiting miR-21, tumor cells lose their ability to multiply and invade tissues, slowing down tumor growth.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
A recent study used AI algorithms to analyze medical imaging and predict treatment response in patients with locally advanced nasopharyngeal carcinoma. The AI-based radiomics model achieved high accuracy in predicting treatment response and prognosis, revealing a link between imaging-derived features and the tumor microenvironment.
An AI model successfully automates lymph node segmentation and extranodal extension classification from pretreatment CT scans in HPV-associated oropharyngeal carcinoma. Predicted extranodal extension is independently associated with worse oncologic outcomes, highlighting the potential for improved treatment planning.
These rare tumors often present with aggressive behavior, early metastasis, and resistance to chemotherapy and radiotherapy. Early detection and disease staging are key factors associated with improved survival.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
UCSF researchers develop a new strategy to prime CAR T cell therapy by combining it with diabetes drugs, increasing the efficacy of NECTIN4-CAR T cells in treating urothelial carcinoma. The study shows that using thiazolidinediones enhances NECTIN4 expression, making tumor cells more susceptible to the treatment.
A clinicopathologic study identified high-grade serous carcinomas in cervical biopsies as secondary to upper genital tract tumors, mostly of endometrial origin. Accurate diagnosis is crucial for proper management.
A recent study identifies four novel proteomic subtypes of GSRCC: Metabolism, Microenvironment Dysregulation, Migration, and Proliferation. Key prognostic biomarkers PRDX2 and DDX27 were also identified, with PRDX2 linked to favorable prognosis and DDX27 associated with poor survival outcomes.
A recent study reveals ADAMTS9-AS2/let-7a-5p axis inhibits the Warburg effect and OSCC progression, suggesting a promising therapeutic target for treatment. The study highlights the importance of metabolic reprogramming in OSCC.
Researchers found that cigarette smoke and reduced DNA repair capacity combine to increase cancer risk, with normal lung cells showing extensive damage after smoke exposure. The study's findings support a 'double hit' model, highlighting the critical role of XPC protein in preventing DNA damage.
Researchers developed a patient-derived organoid library to study chemotherapy resistance in esophageal cancer. Lab-grown mini-tumors showed increased activity in the NRF2 pathway, suggesting potential biomarkers for predicting chemotherapy resistance.
A new machine learning algorithm, SAVANA, has been developed to accurately detect structural variations in cancer genomes using long-read sequencing data. The algorithm was tested on 99 human tumour samples and showed high consistency with current clinical standards.
Bcl6 inhibits Treg cell lineage stability, allowing for increased CD8+ T cell infiltration and enhanced anti-tumor response. Bcl6 inhibitor FX1 also synergizes with PD-1/PD-L1 ICB therapy.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
A cohort study found that long-term survival was similar among patients with low-risk early-stage cervical carcinoma who underwent simple, modified, or radical hysterectomy. These findings support the use of simple hysterectomy in select patients.
This study compares laser-guided technology to conventional manual percutaneous lung biopsy, finding that laser-guided technology can reduce operational time and needle adjustments. However, it did not reduce complication rates or improve pathological diagnosis accuracy compared to traditional methods.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A patient with adenoid cystic carcinoma was successfully treated with step-and-shoot proton arc therapy at Corewell Health William Beaumont University Hospital. The treatment showed minimal side effects, including only light skin discoloration, and the patient remains cancer-free.
Researchers have discovered that pyrvinium pamoate, a common pinworm medication, can inhibit cancer cell growth and reverse neuroendocrine features in Merkel cell carcinoma. The medication also reduced tumor growth in mouse models of the disease.
The SNMMI Mars Shot Research Fund has awarded a $100,000 fellowship to Dr. Randy Ye for his research on FAPI PET imaging for detecting invasive lobular carcinoma. The study aims to assess the ability of FAPI PET and FDG PET to detect tumors and evaluate its impact on patient care.
A novel circular RNA, circTP63-N, generated by back-splicing exons 2–4 of the TP63 gene is significantly downregulated in nasopharyngeal carcinoma (NPC) tissues. Restoring its expression effectively inhibits NPC cell proliferation and metastasis via engagement with HSP90AB1 to modulate the YAP1/Hippo signaling pathway.
Researchers have made a breakthrough in treating thymic carcinoma by combining immune checkpoint inhibitors with platinum-based chemotherapy. The MARBLE study found that atezolizumab combined with carboplatin and paclitaxel achieved an objective response rate of 56% and median progression-free survival of 9.6 months.
A randomized study found that active monitoring for low-risk ductal carcinoma in situ did not increase invasive cancer risk compared to guideline-concordant care. Women on active monitoring had comparable rates of disease recurrence and survival.
Women with low-risk ductal carcinoma in situ reported similar experiences undergoing active monitoring versus guideline-concordant care. The study found that both approaches had comparable lived experiences during the 2-year follow-up period.
A phase 3 study demonstrated nearly 75% complete cancer remission in patients with high-risk bladder cancer unresponsive to BCG therapy. The novel treatment, cretostimogene grenadenorepvec, was well-tolerated and did not require bladder removal surgery.
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
A new study from the University of Texas M. D. Anderson Cancer Center found that at least 3% of normal breast tissue cells in healthy women contain chromosome abnormalities associated with invasive breast cancer, which may guide future approaches to early detection.